Sign in

CIK 0001714899

  • Large accelerated filer

Denali Therapeutics Inc.

Sign in to watch
Ticker
DNLI
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
463872213
Phone
+1 650-866-8547
Business address
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
  1. 4 Open-market sale Director sold 3,339 shares at $20.81 ($69,485)
  2. 4 Grant or award President and CEO acquired 54,180 shares (grant or award)
  3. 4 Grant or award COFO and Secretary acquired 54,180 shares (grant or award)
  4. 4 Grant or award Chief Medical Officer acquired 54,180 shares (grant or award)
  5. 4 Planned sale Director sold 30,000 shares at $20.25 ($607,500)
  6. 4 Planned sale Director sold 3,080 shares at $20.91 ($64,403)
  7. 4 Option exercise COFO and Secretary acquired 6,708 shares (option exercise)
  8. 4 Option exercise Chief Medical Officer acquired 17,845 shares (option exercise)
  9. 4 Option exercise COFO and Secretary acquired 20,516 shares (option exercise)
  10. 4 Planned sale Director sold 59,441 shares at an average $32.51 ($1,932,665)
  11. 4 Planned sale COFO and Secretary sold 15,558 shares at an average $29.91 ($465,286)
  12. 4 Planned sale Director sold 1,020 shares at $30.00 ($30,600)
  13. 4 Planned sale Director sold 3,080 shares at $27.07 ($83,376)
  14. 4 Planned sale President and CEO sold 40,000 shares at $27.69 ($1,107,600)
  15. 4 Planned sale Director sold 30,000 shares at $29.03 ($870,900)
  16. 4 Planned sale Director sold 1,020 shares at $30.00 ($30,600)
  17. 4 Planned sale Director sold 3,080 shares at an average $25.00 ($77,007)
  18. 4 Open-market sale President and CEO sold 2,260 shares at $23.79 ($53,765)
  19. 4 Open-market sale Director sold 1,727 shares at $23.79 ($41,085)
  20. 4 Planned sale COFO and Secretary sold 8,353 shares at an average $23.99 ($200,401)

Page 3 of 22 · 436 filings